Skip to content

FSH Followed by HMG vs FSH Plus HMG in IVF

Follicle Stimulating Hormone (FSH) Followed by Human Menopausal Gonadotropin (HMG) Versus FSH Plus HMG During Controlled Ovarian Stimulation for in Vitro Fertilization

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04385342
Enrollment
530
Registered
2020-05-12
Start date
2020-06-30
Completion date
2022-08-31
Last updated
2020-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IVF

Keywords

ovarian stimulation, subfertility, FSH, HMG

Brief summary

The aim of this study is to compare the clinical outcomes of sequential administration of FSH and HP-hMG FSH alone versus concomitant administration of FSH and HP-hMG during controlled ovarian stimulation in IVF cycles.

Detailed description

Women who are planned to be subjected to IVF/ICSI through COS by long GnRHa protocol will be assessed for possibility of participation in our study. Eligible participants in our study will be those with regular menstrual cycle (21-35 days) and normal uterine anatomy (confirmed by transvaginal ultrasound examination and in some cases hysteronsalpingography and hysteroscopy). Women with any of the following criteria will be excluded from the study: 1) age \< 20 or \> 37 years; 2) body mass index (BMI) \< 18 or \> 25 kg/m2; 3) low ovarian reserve (AFC \< 7 and/or AMH \< 1.1 ng/ml); 4) presence of polycystic ovarian syndrome (PCOS), endometrioma or hydrosalpinx; 5) history of chemotherapy, radiotherapy or ovarian surgery; 6) the husband needs testicular biopsy to obtain sperm; or 7) previous implantation failure. A written informed consent will be taken from each women selected to participate before inclusion in the study. All women participating in the study will start GnRHa on day 21 of the preceding cycle and when down regulation occurs each woman will be randomly allocated into one of the two groups; group 1 and group 2. Women in group 1 will receive 225 IU FSH alone from day one of ovarian stimulation and when the follicular diameters reaches 10-12 mm, the 150 IU HP-hMG will substitute FSH and continued to the day of triggering. Women in group 2 will receive 150 IU FSH plus 75 IU HP-hMG from day one of ovarian stimulation and 150IU HP-HMG when the follicular diameters reaches 10-12 mm till day of triggering. The randomization will be simple and balanced (1:1) and will be carried out by a nurse through sealed, unlabeled, opaque envelopes containing computer-generated random numbers. The data assesor will be blinded to group assignment. In both groups, estradiol and LH will be measured on the third day of menstruation before start of stimulation and on day 6 of stimulation TVS will be performed. Progesterone and E2 will be measured and on day of triggering. The primary outcome measure of this study will be the ongoing pregnancy rate. The secondary outcomes measures will be cancellation rate, the number of oocytes retrieved, the number of embryos, the number of vitrified embryos, the clinical pregnancy rate, the implantation rate, OHSS rate, multiple pregnancy rate, and the miscarriage rate.

Interventions

DRUGHP-hMG

Controlled ovarian stimulation by FSH followed by HMG versus FSH plus HMG

DRUGFSH

Controlled ovarian stimulation by FSH followed by HMG versus FSH plus HMG

Sponsors

Mansoura University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 37 Years
Healthy volunteers
No

Inclusion criteria

* Women who are planned to be subjected to IVF/ICSI through COS by long GnRHa protocol. * Women with regular menstrual cycle (21-35 days) and normal uterine anatomy (confirmed by transvaginal ultrasound examination and in some cases hysteronsalpingography and hysteroscopy).

Exclusion criteria

* Age \< 20 or \> 37 years. * Body mass index (BMI) \< 18 or \> 30 kg/m2. * Low ovarian reserve (AFC \< 7 and/or AMH \< 1.1 ng/ml). * Presence of polycystic ovarian syndrome (PCOS). * Endometrioma or hydrosalpinx. * History of chemotherapy, radiotherapy or ovarian surgery. * The husband needs testicular biopsy to obtain sperm. * Previous implantation failure.

Design outcomes

Primary

MeasureTime frameDescription
Ongoing pregnancy rate12 weeks gestational ageNumber of ongoing pregnancies (defined as pregnancies passed beyond 12 weeks gestational age) divided by the number of women randomized

Secondary

MeasureTime frameDescription
Clinical pregnancy rate6 weeks after embryo transferNumber of clinical pregnancies (defined as presence of at least one intrauterine gestational sac with fetal pole and cardiac activity on TVS scan at 4-6 weeks after the ET) divided by the number of women randomized
Implantation rate6 weeks after embryo transferNumber of gestational sacs on TVS scan at 4-6 weeks after ET divided by the number of transferred embryos
Miscarriage rate12 weeks gestational ageNumber of first trimester miscarriages (before 12 weeks gestational age) divided by the number of clinical pregnancies

Countries

Egypt

Contacts

Primary ContactAhmed Gibreel, MD
ahmedfathgi@yahoo.com01221191133

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026